CG Oncology, Inc. (CGON) closed the last trading session at $26.42, gaining 2.2% over the past four weeks, but there could be ...

In a report released today, Sean Laaman from Morgan Stanley maintained a Buy rating on CG Oncology, Inc. (CGON – Research Report), with a price ...

We recently published a list of the 12 Best IPO Stocks to Buy in 2025. In this article, we are going to take a look at where ...

Durability Results from BOND-003 data will be presented as a late breaker as part of AUA’s Practice-changing, Paradigm-shifting Clinical Trials ...

Full Year 2024 Results Key Financial Results Net loss: US$88.0m (loss widened by 30% ...

March 28, 2025 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing ...

HC Wainwright restated their buy rating on shares of CG Oncology (NASDAQ:CGON – Free Report) in a research report released on ...

Across the recent three months, 4 analysts have shared their insights on CG Oncology CGON -2.73% Get Free Report , expressing a variety of opinions spanning from bullish to bearish. Summarizing their ...

CG Oncology, Inc. announced that it will present a late-breaking abstract and three posters at the 40th Annual European Association of Urology (EAU) Congress in Madrid from March 21-24 ...

Across the recent three months, 4 analysts have shared their insights on CG Oncology (NASDAQ:CGON), expressing a variety of opinions spanning from bullish to bearish. Summarizing their recent ...

March 28, 2025 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing ...